Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Overview of attention for article published in New England Journal of Medicine, December 2011

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 10 news outlets
blogs: 4 blogs
policy: 3 policy sources
twitter: 62 X users
patent: 71 patents
facebook: 4 Facebook pages

wikipedia: 1 Wikipedia page
googleplus: 2 Google+ users
f1000: 1 research highlight platform
guideline: 7 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 5 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 16 news stories from 10 outlets.

EVERGREEN Study: Everolimus Shows Modest Benefit After CDK4/6 Progression - OncoDaily

Oncodaily, 01 Aug 2026

Treatment selection after progression on endocrine therapy plus a CDK4/6 inhibitor remains a complex part of managing estrogen…

San Antonio Breast Cancer Symposium: More to Come on 2011 Practice Changers

Pediatric News , 30 Sep 2024

– The pairing of mTOR and aromatase inhibition, as validated by the combination of everolimus (Afinitor) and exemestane (Aromasin…

Clinical Challenges: Options After CDK4/6 Inhibitors in Breast Cancer

MedPage Today, 30 Sep 2022

Clinical Challenges > ESMO: Metastatic Breast Cancer Rapidly changing landscape has brought new targeted agents and made…

Clinical Insights: October 2019

Oncology Nursing News, 13 May 2021

Release Date: October 22, 2019 Expiration Date: October 22, 2020 This activity is provided free of charge.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 12 additional news stories.